# psoriasis - gpt-5.6-luna

- Benchmark system: raw
- Repeat: 6
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 3907
- Completion tokens: 5235
- Reasoning tokens: 
- Total tokens: 9142
- API requests reported: 
- Elapsed seconds: 97.595
- Final benchmark system: raw; file rank 4/5; original repeat 6; model vendor: OpenAI

---
## 1. Overall biological interpretation

The lesional skin profile shows a strong, internally coherent inflammatory and epidermal-remodeling state rather than an isolated single-gene abnormality. The dominant features are:

- **IL-36/IL-20-family inflammatory signaling**, including marked induction of **IL36A, IL36G, IL19, IL20, IL26**, and the counter-regulatory antagonist **IL36RN**.
- **Epidermal antimicrobial and alarmin activation**, with very large increases in **DEFB4A/DEFB4B, DEFB103A/DEFB103B, PI3, S100A7, S100A7A, S100A8, S100A12**, and related innate-defense genes.
- **Keratinocyte hyperplasia, altered differentiation, and barrier remodeling**, supported by **KRT6A, SPRR2A/B/D/E/F/G, SPRR3, LCE3A/LCE3D, SERPINB3/B4, GJB2/GJB6**, and **S100A7-family** genes.
- **Myeloid/neutrophil-associated inflammation**, suggested by **S100A8, S100A12, TCN1, CXCR2, PLBD1, GPR15LG**, and **CXCL13**.
- **Cell-cycle and tissue-remodeling changes**, including **RRM2, CCNE1, WNT5A, HPSE**, and **PLA2G4D/E**.

The results are highly statistically significant, with FDR values generally far below \(10^{-60}\), and many effect sizes are large. This strongly supports a disease-state difference. However, the analysis is based on bulk lesional skin, so it does not establish whether a signal is caused by altered expression within a cell type, increased abundance of that cell type, or both. It also supports association with psoriasis lesions, not causality.

---

## 2. Core biological programs

### Program 1: IL-36/IL-20-family inflammatory circuit

**Direction:** Upregulated in lesional skin.

**Major supporting genes:**  
**IL36A** (log2FC 11.37), **IL36G** (5.68), **IL19** (7.58), **IL20** (5.67), **IL26** (4.36), **IL36RN** (3.01), **TNIP3** (7.28), **IRAK2** (2.08), **ZC3H12A** (3.85).

**Most appropriate pathway terminology:**

- **GO Biological Process:** cytokine-mediated signaling pathway; inflammatory response
- **Reactome:** cytokine signaling in immune system; innate immune system
- **Hallmark:** inflammatory response
- IL-36 signaling is more appropriately interpreted as a cytokine-receptor signaling module than as a single universal pathway label.

**Interpretation:**  
The coordinated induction of multiple IL-36 and IL-20-family cytokines is stronger evidence than the presence of any individual cytokine. IL-36A and IL-36G are particularly notable because they are produced in inflamed epidermis and can amplify keratinocyte and myeloid inflammatory programs. The concurrent increase in **IL36RN**, which encodes an IL-36 receptor antagonist, indicates that the tissue is also mounting a counter-regulatory response. Thus, the data suggest an activated cytokine circuit with simultaneous negative feedback rather than unopposed signaling.

**Evidence strength:** Strong direct transcriptomic evidence; strong pathway and disease-association concordance with established psoriasis biology.

**Limitations:**  
The data do not demonstrate cytokine protein production, receptor activation, or signaling flux. IL-36/IL-20-family induction could be downstream of another inflammatory driver. The dataset does not include sufficient receptor, phosphoprotein, or perturbation data to identify the initiating cytokine.

---

### Program 2: Antimicrobial peptide and innate epithelial defense response

**Direction:** Strongly upregulated.

**Major supporting genes:**  
**DEFB4A** (11.18), **DEFB4B** (11.03), **DEFB103A/B** (approximately 5.76), **PI3** (9.24), **S100A7** (7.09), **S100A7A** (9.83), **S100A8** (7.73), **S100A12** (8.33), **GJB2**, **GJB6**, **FABP5**, **TCN1**.

**Most appropriate pathway terminology:**

- **GO:** antimicrobial humoral response; defense response to bacterium; innate immune response
- **Reactome:** antimicrobial peptides
- **Hallmark:** inflammatory response, with epithelial defense genes representing a more specific disease-associated component

**Interpretation:**  
The simultaneous induction of several beta-defensins, PI3/elafin-related protease-inhibitory defense genes, S100 alarmins, and epithelial structural genes indicates a broad activation of the lesional epidermal innate-defense state. This is not merely a generic inflammatory signature: it includes genes involved in antimicrobial activity, epithelial stress responses, and intercellular barrier function. The magnitude of **DEFB4A/B** induction is especially compatible with an inflammatory keratinocyte phenotype, although it does not identify the upstream cytokine.

**Evidence strength:** Very strong direct dataset evidence, supported by multiple independent gene families and established epithelial biology.

**Limitations:**  
Antimicrobial peptide induction is not specific to psoriasis and can occur in infection, wound healing, atopic inflammation, and other dermatitis states. Some genes, particularly **S100A8/A12** and **TCN1**, may also reflect infiltrating myeloid cells. Functional antimicrobial activity cannot be inferred from RNA abundance alone.

---

### Program 3: Keratinocyte hyperplasia, differentiation, and barrier remodeling

**Direction:** Upregulated.

**Major supporting genes:**  
**KRT6A** (4.30), **SPRR2A/B/D/E/F/G**, **SPRR3**, **LCE3A** (8.30), **LCE3D** (5.31), **SERPINB3** (6.74), **SERPINB4** (9.12), **SERPINB13**, **GJB2**, **GJB6**, **S100A7/A7A**, **KLK13**, **PRSS27**, **TMPRSS11D**.

**Most appropriate pathway terminology:**

- **GO:** epidermis development; keratinocyte differentiation; skin development; epithelial cell differentiation
- **Reactome:** keratinization
- **Hallmark:** epithelial–mesenchymal transition is not an appropriate primary label here; **epithelial differentiation/keratinization** is more accurate, although no single Hallmark pathway fully captures this program.

**Interpretation:**  
The coordinated induction of keratins, small proline-rich proteins, late cornified envelope genes, clade B serpins, connexins, and epidermal proteases indicates substantial remodeling of keratinocyte state. This pattern is consistent with lesional epidermal hyperplasia, altered terminal differentiation, and barrier adaptation. The signal is biologically related to, but distinct from, the antimicrobial program: some genes such as **S100A7** participate in both inflammatory defense and keratinocyte stress.

**Evidence strength:** Strong direct evidence from numerous genes with complementary structural and differentiation functions; consistent with known psoriasis tissue morphology.

**Limitations:**  
Bulk transcriptomics cannot distinguish increased expression per keratinocyte from increased epidermal thickness or altered proportions of basal, suprabasal, and differentiated keratinocytes. Some genes are responsive to tissue injury and are not psoriasis-specific. Histologic correlation is needed.

---

### Program 4: Myeloid/neutrophil-associated inflammatory recruitment

**Direction:** Upregulated.

**Major supporting genes:**  
**S100A8, S100A12, TCN1, CXCR2, PLBD1, GPR15LG, CXCL13, ADAP2, ACP7**, and **S100A7/A7A**.

**Most appropriate pathway terminology:**

- **GO:** leukocyte chemotaxis; neutrophil chemotaxis; myeloid leukocyte activation
- **Reactome:** neutrophil degranulation; chemokine receptors bind chemokines
- **KEGG:** cytokine–cytokine receptor interaction, with caution because the input does not provide pathway enrichment statistics

**Interpretation:**  
The combination of neutrophil-associated antimicrobial proteins, S100A8/A12, a chemotaxis receptor (**CXCR2**), and chemotactic or immune-organizing signals supports recruitment or accumulation of inflammatory myeloid cells in lesions. **CXCL13** may indicate broader immune-cell organization and should not be interpreted as a purely neutrophil-specific marker. This program complements the keratinocyte cytokine signature: inflamed epidermal cells may contribute recruitment signals, while infiltrating myeloid cells contribute S100 and granule-associated transcripts.

**Evidence strength:** Strong direct expression evidence for a myeloid/inflammatory component; moderate pathway-level interpretation because cell identity is inferred from bulk tissue.

**Limitations:**  
This is particularly vulnerable to cell-composition confounding. The data do not establish the precise abundance or phenotype of neutrophils, monocytes, dendritic cells, or lymphocytes. **S100A8/A12** are not exclusive to one myeloid population, and **CXCL13** has multiple cellular sources.

---

### Program 5: Lesional proliferation and tissue remodeling

**Direction:** Upregulated.

**Major supporting genes:**  
**RRM2** (2.72), **CCNE1** (2.56), **CDK5R1**, **WNT5A** (2.53), **HPSE** (2.92), **PLA2G4D** (4.61), **PLA2G4E** (2.47), **WNT5A**, **KRT6A**, and **SERPINB3/B4**.

**Most appropriate pathway terminology:**

- **GO:** DNA replication; mitotic cell cycle; extracellular matrix organization; tissue remodeling
- **Reactome:** cell cycle; heparan sulfate degradation; arachidonic acid metabolism
- **Hallmark:** E2F targets and G2M checkpoint may be relevant for the proliferative component, but formal enrichment was not supplied

**Interpretation:**  
**RRM2** and **CCNE1** support increased keratinocyte proliferation or a greater representation of cycling cells. **HPSE**, **WNT5A**, and phospholipase-related genes suggest extracellular, lipid-mediated, and wound-like tissue remodeling. Together with the keratinization program, these genes are consistent with an expanded and actively remodeling lesional epidermis.

**Evidence strength:** Moderate-to-strong direct evidence, but based on fewer genes than the cytokine or antimicrobial programs.

**Limitations:**  
The proliferative signal is not as specific as the IL-36 or defensin signals. It may be influenced by epidermal thickness, disease severity, wound-like repair, or sampling depth. No histologic proliferation marker or cell-cycle scoring was provided.

---

## 3. Key genes and interaction modules

The following candidates are prioritized as modules rather than as isolated “drivers.”

1. **IL36A–IL36G–IL36RN module**  
   - **Direction:** IL36A, IL36G, and IL36RN all upregulated.  
   - **Role:** Central inflammatory cytokine and feedback module.  
   - **Relationship:** **Regulatory/pathway relationship**, not demonstrated direct physical interaction. IL36RN is functionally antagonistic to IL-36 receptor signaling, but this dataset does not show receptor occupancy or causality.  
   - **Evidence:** Direct expression plus established cytokine biology. The simultaneous antagonist induction argues for active feedback.

2. **IL19–IL20–IL26 inflammatory effector module**  
   - **Direction:** All upregulated.  
   - **Role:** Supports epithelial inflammatory amplification and immune communication.  
   - **Relationship:** **Pathway co-membership and regulatory/indirect cytokine relationships**; no direct physical interaction is implied.  
   - **Evidence:** Direct coordinated expression and cytokine-network biology. Upstream source and target cells remain unresolved.

3. **DEFB4A/DEFB4B–DEFB103A/B antimicrobial module**  
   - **Direction:** Strongly upregulated.  
   - **Role:** Epithelial antimicrobial defense and inflammatory barrier response.  
   - **Relationship:** **Functional pathway co-membership**; the encoded peptides are not necessarily direct protein-interaction partners.  
   - **Evidence:** Multiple independent defensin genes with very large effects. This is a robust lesional signature but is not psoriasis-specific.

4. **S100A7/A7A–S100A8–S100A12 alarmin module**  
   - **Direction:** Upregulated.  
   - **Role:** Links keratinocyte stress, antimicrobial defense, and myeloid inflammation.  
   - **Relationship:** **Pathway co-membership and indirect inflammatory signaling**. S100 proteins can have protein interactions in specific contexts, but no direct physical interaction is demonstrated by this dataset.  
   - **Evidence:** Strong expression signal and established inflammatory biology; cell-of-origin ambiguity remains important.

5. **SPRR/LCE/SERPIN keratinocyte differentiation module**  
   - **Direction:** Broadly upregulated.  
   - **Role:** Epidermal differentiation, cornification, barrier adaptation, and protease control.  
   - **Relationship:** **Pathway co-membership and coordinated transcriptional response**, not direct physical interaction.  
   - **Evidence:** Numerous genes from related epidermal gene families, making this a strong network-level signal.

6. **CXCR2–myeloid recruitment module**  
   - **Direction:** CXCR2 upregulated, with S100A8/A12, TCN1, PLBD1, and GPR15LG also increased.  
   - **Role:** Potential inflammatory-cell recruitment and accumulation.  
   - **Relationship:** **Receptor–ligand/regulatory pathway relationship is plausible**, but the relevant ligands and responding cell types were not measured sufficiently to establish a specific CXCR2 axis.  
   - **Evidence:** Direct expression plus chemotaxis biology; composition confounding is a major alternative explanation.

7. **CXCL13 immune-organization signal**  
   - **Direction:** Upregulated.  
   - **Role:** May reflect local immune-cell recruitment or organization.  
   - **Relationship:** **Indirect chemokine-mediated relationship**; no direct interaction with the other modules is implied.  
   - **Evidence:** Strong differential expression, but source-cell and functional interpretation are uncertain.

8. **RRM2–CCNE1 proliferative module**  
   - **Direction:** Both upregulated.  
   - **Role:** DNA synthesis and cell-cycle activation, compatible with epidermal hyperplasia.  
   - **Relationship:** **Pathway co-membership and regulatory cell-cycle relationship**, not necessarily direct physical interaction.  
   - **Evidence:** Direct expression of two cell-cycle-associated genes; requires histologic and cell-type validation.

9. **WNT5A–HPSE–PLA2G4D/E remodeling module**  
   - **Direction:** All upregulated.  
   - **Role:** Putative tissue remodeling, extracellular matrix/heparan-sulfate biology, and inflammatory lipid mediator production.  
   - **Relationship:** **Indirect or putative pathway-level relationship**; no direct interaction is established.  
   - **Evidence:** Biologically plausible but less strongly supported than the cytokine, defensin, and keratinocyte modules.

10. **CD274 inflammatory checkpoint signal**  
    - **Direction:** CD274/PD-L1 upregulated (3.44).  
    - **Role:** May represent local immune-regulatory feedback in inflamed skin.  
    - **Relationship:** **Regulatory receptor–ligand relationship** with PD-1-positive immune cells is biologically plausible, but those partners were not measured here.  
    - **Evidence:** Direct expression plus known immune-checkpoint biology; not sufficient to infer functional immune suppression or therapeutic relevance in psoriasis.

---

## 4. Validation priorities

### 1. Validate the IL-36-centered epithelial inflammatory circuit  
**Classification:** Mechanistic hypothesis  
**Priority:** High  
**Current evidence:** Strong coordinated induction of **IL36A, IL36G, IL19, IL20, IL26**, and **IL36RN**.  
**External evidence:** IL-36 signaling is well established as relevant to inflammatory epidermal disease and psoriasis-like biology. However, the present data do not show that IL-36 is upstream of the entire signature.  
**Next step:** Measure IL-36A/G and IL-36RN protein in lesional epidermis, assess IL-36 receptor pathway activation, and perturb IL-36 signaling in primary keratinocytes or lesional skin explants.  
**Conclusion level:** **Supported hypothesis**, not established causality.

### 2. Resolve epithelial versus infiltrating-myeloid contributions  
**Classification:** Confounding or composition check  
**Priority:** High  
**Current evidence:** Strong epithelial genes coexist with **S100A8, S100A12, TCN1, PLBD1, CXCR2**, and other myeloid-associated transcripts.  
**External evidence:** These genes are compatible with neutrophil/myeloid infiltration but are not entirely cell-type exclusive.  
**Next step:** Perform single-cell or spatial transcriptomics, or use multiplex immunostaining for keratinocytes, neutrophils, monocytes, and dendritic cells. Computational deconvolution can be useful but should be validated experimentally.  
**Conclusion level:** **Established concern**, with the exact cellular attribution unresolved.

### 3. Test whether the antimicrobial program is functionally active or merely transcriptional  
**Classification:** Biomarker and mechanistic hypothesis  
**Priority:** High  
**Current evidence:** Very large increases in **DEFB4A/B, DEFB103A/B, PI3, S100A7/A7A**, and related genes.  
**External evidence:** These genes are recognized components of inflamed epidermal defense, but they can also increase in infection or tissue injury.  
**Next step:** Quantify peptide/protein abundance and assess antimicrobial activity in lesional tissue or conditioned media; compare psoriasis with infectious and non-psoriatic inflammatory dermatoses.  
**Conclusion level:** **Established transcriptional association; supported functional hypothesis.**

### 4. Evaluate the proliferative/remodeling state in relation to lesion severity  
**Classification:** Biomarker  
**Priority:** Moderate-high  
**Current evidence:** **RRM2, CCNE1, KRT6A, WNT5A, HPSE**, and lipid-remodeling genes are increased.  
**External evidence:** Psoriatic lesions commonly exhibit epidermal hyperplasia and altered differentiation, but these genes are not specific enough to establish disease activity independently.  
**Next step:** Correlate expression with epidermal thickness, Ki-67 labeling, disease severity, lesion age, and treatment status.  
**Conclusion level:** **Supported hypothesis.**

### 5. Assess whether CXCL13/CD274 indicate a distinct immune microenvironment  
**Classification:** Interaction / network hypothesis  
**Priority:** Moderate  
**Current evidence:** **CXCL13** and **CD274** are upregulated, alongside inflammatory cytokines and myeloid-associated genes.  
**External evidence:** Both genes can reflect immune organization or local immune regulation in inflamed tissues, but their roles in this specific bulk-lesion profile are not defined.  
**Next step:** Spatially localize CXCL13 and PD-L1 to keratinocytes, myeloid cells, or lymphocytes and measure corresponding receptor-positive cells.  
**Conclusion level:** **Exploratory hypothesis.**

Drug availability should not be used as evidence that any of these genes is an effective therapeutic target. Therapeutic prioritization would require target engagement, cell-specific causality, and clinical-response evidence.

---

## 5. Evidence grounding

- **Direct dataset evidence:** Very strong for the existence of a lesional transcriptional state. Most leading genes have large effect sizes and extremely low FDR values.
- **Pathway/ontology evidence:** Strong for antimicrobial defense, epidermal differentiation, inflammatory cytokine signaling, and cell-cycle biology based on known gene functions. Formal enrichment statistics were not supplied, so pathway claims should be considered functionally annotated interpretations rather than demonstrated enrichment results.
- **Protein-interaction evidence:** Not established by this dataset. The proposed modules primarily represent pathway co-membership, regulatory relationships, or indirect signaling.
- **Disease-association evidence:** The IL-36, keratinocyte, antimicrobial peptide, and epidermal remodeling patterns are broadly concordant with established psoriasis literature.
- **Expression/tissue evidence:** The gene set is compatible with lesional epidermis and inflammatory infiltrates, but bulk tissue prevents confident cell-of-origin assignment.
- **Genetic/clinical evidence:** No genotype, longitudinal outcome, severity, treatment-response, or clinical covariate information was provided. No causal or prognostic conclusions can therefore be drawn.
- **Drug/therapeutic evidence:** Not provided and should not be inferred from the transcriptomic associations.

The different evidence categories are not fully independent. For example, established psoriasis literature often derives from expression, histology, and cytokine studies that overlap biologically with the present gene set. Therefore, concordance strengthens biological plausibility but does not constitute independent proof of mechanism.

---

## 6. Major limitations and alternative explanations

1. **Cell-composition differences**  
   Increased immune-cell abundance may explain part of the S100A8/A12, TCN1, PLBD1, CXCR2, and related signal. Investigate using single-cell/spatial methods, deconvolution, and immunostaining.

2. **Epidermal thickness and sampling depth**  
   Lesional skin may contain more keratinocytes or different epidermal layers than normal skin. This can inflate barrier, cornification, and proliferation signals without requiring equivalent per-cell induction. Histology and layer-specific sampling are important.

3. **Inflammation and tissue injury are not psoriasis-specific**  
   Defensins, S100 proteins, KRT6A, SERPINB3/B4, and cytokines can be induced in infection, wounds, and other inflammatory dermatoses. Disease-specificity should be tested against multiple dermatologic controls.

4. **Treatment exposure and disease severity**  
   Topical or systemic therapy, lesion chronicity, and severity could alter cytokine, antimicrobial, and proliferation programs. Clinical metadata and matched untreated samples are needed.

5. **Association-versus-causation ambiguity**  
   Even the most statistically extreme genes may be downstream markers of the lesion state. Perturbation experiments, longitudinal sampling, and response-linked analyses are required to distinguish drivers from consequences.

### Overall conclusion

The strongest interpretation is that psoriatic lesional skin exhibits a coordinated **IL-36/IL-20 inflammatory, antimicrobial, keratinocyte-remodeling, and myeloid-recruitment state**, accompanied by epidermal proliferation and tissue remodeling. The data robustly establish differential expression and strongly support these biological programs, but they do not by themselves establish the upstream causal hierarchy or therapeutic value of individual genes.
